Researchers study mitochondrial function, potential new therapeutic target for Alzheimer's disease

February 15, 2012

Researchers at Rush University Medical Center are conducting an early phase clinical trial of a novel drug therapy for patients with dementia due to Alzheimer's disease. The drug is a new compound called MSDC-0160, which is an insulin sensitizer that modulates mitochondrial metabolism.

Mitochondria are known as the powerhouses of cells, including . Mitochondria help convert glucose, which is thought to be the main fuel source for brain cells, into energy.

Mitochondrial function may play an important role in brain . Reduced mitochondrial function in converting glucose into energy seems to occur early in Alzheimer's disease.

"In this initial study, we are trying to determine if MSDC-0160 improves the brain's use of glucose," said Dr. Raj C. Shah, director of the Rush Memory Clinic at the Rush Alzheimer's Disease Center and principal investigator of the study. "We can measure brain cell glucose use using fluordeoxyglucose positron-emission tomography (FDG-PET), a special brain imaging test."

MSDC-0160 also is being developed as a treatment for diabetes by Metabolic Solutions Development Company, a Kalamazoo, Michigan-based developer of new therapeutics to treat associated with age-related mitochondrial dysfunction.

An earlier mouse model study indicated that MSDC-0160 may reduce Alzheimer's like pathology in mouse brains.

As a result of this finding, Rush is conducting a Phase IIa trial that will help determine if the drug therapy affects in specific regions of the brain. Rush is the only medical center in the U.S. conducting the double-blind, placebo-controlled study.

Patients who are 55-85 years of age, who do not have diabetes, and who have been diagnosed with mild dementia due to Alzheimer's disease are being enrolled in the clinical trial. Forty patients in the study will be randomized to receive either MSDC-0160 or a placebo once daily for 90 days.

The study was awarded a grant by the Alzheimer's Drug Discovery Foundation (ADDF). The mouse model study was conducted by Doug Feinstein, PhD, at the University of Illinois at Chicago.

Related Stories

Recommended for you

Could olfactory loss point to Alzheimer's disease?

August 16, 2017
By the time you start losing your memory, it's almost too late. That's because the damage to your brain associated with Alzheimer's disease (AD) may already have been going on for as long as twenty years. Which is why there ...

New Machine Learning program shows promise for early Alzheimer's diagnosis

August 15, 2017
A new machine learning program developed by researchers at Case Western Reserve University appears to outperform other methods for diagnosing Alzheimer's disease before symptoms begin to interfere with every day living, initial ...

Brain scan study adds to evidence that lower brain serotonin levels are linked to dementia

August 14, 2017
In a study looking at brain scans of people with mild loss of thought and memory ability, Johns Hopkins researchers report evidence of lower levels of the serotonin transporter—a natural brain chemical that regulates mood, ...

Alzheimer's risk linked to energy shortage in brain's immune cells

August 14, 2017
People with specific mutations in the gene TREM2 are three times more likely to develop Alzheimer's disease than those who carry more common variants of the gene. But until now, scientists had no explanation for the link.

Scientists reveal role for lysosome transport in Alzheimer's disease progression

August 7, 2017
Researchers from Yale University School of Medicine have discovered that defects in the transport of lysosomes within neurons promote the buildup of protein aggregates in the brains of mice with Alzheimer's disease. The study, ...

Mild cognitive impairment and Alzheimer's diagnoses trigger lower self-ratings of quality of life

August 3, 2017
Researchers at Penn Medicine have discovered that a patient's awareness of a diagnosis of cognitive impairment may diminish their self-assessment of quality of life. In a study published this month in the Journal of Gerontology: ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.